SQI Diagnostics Amends Purchase Deal of Scienion to Push Back Termination Date | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SQI Diagnostics today announced it has amended its deal to buy Scienion in order to push back the date by which the deal can be terminated.

The termination date is now Oct. 5, changed from the original date of Sept. 30. No reason was given for the change. SQI also has agreed to issue an additional 173,797 common shares of its stock to Scienion in consideration of the extension, the Toronto-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.